S&P 500   3,000.76 (+0.16%)
DOW   26,851.80 (+0.24%)
QQQ   192.05 (+0.10%)
AAPL   242.75 (+1.16%)
MSFT   136.05 (-0.23%)
GOOGL   1,255.76 (+1.17%)
AMZN   1,766.38 (+0.04%)
NVDA   194.64 (-0.50%)
MU   44.30 (-0.81%)
BABA   168.86 (-0.61%)
GE   9.03 (-0.44%)
TSLA   254.39 (-0.47%)
ACB   3.59 (+0.28%)
PRI   125.46 (-0.27%)
GILD   65.91 (+0.08%)
DIS   132.06 (-0.26%)
S&P 500   3,000.76 (+0.16%)
DOW   26,851.80 (+0.24%)
QQQ   192.05 (+0.10%)
AAPL   242.75 (+1.16%)
MSFT   136.05 (-0.23%)
GOOGL   1,255.76 (+1.17%)
AMZN   1,766.38 (+0.04%)
NVDA   194.64 (-0.50%)
MU   44.30 (-0.81%)
BABA   168.86 (-0.61%)
GE   9.03 (-0.44%)
TSLA   254.39 (-0.47%)
ACB   3.59 (+0.28%)
PRI   125.46 (-0.27%)
GILD   65.91 (+0.08%)
DIS   132.06 (-0.26%)
Log in

Imugene Stock Price, News & Analysis (ASX:IMU)

A$0.02
0.00 (0.00 %)
(As of 10/23/2019 11:07 AM ET)
Today's Range
A$0.02
Now: A$0.02
A$0.02
50-Day Range
A$0.02
MA: A$0.02
A$0.02
52-Week Range
A$0.01
Now: A$0.02
A$0.03
Volume19.31 million shs
Average VolumeN/A
Market Capitalization$79.42 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Imugene Limited, an immuno-oncology biopharmaceutical company, develops mimotopes and small molecule drug candidates in Australia. Its lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu receptors, which are expressed on the surface of tumors, including gastric, breast, ovarian, and pancreatic cancers. The company's HER-Vaxx has completed a Phase I clinical trial to treat breast cancer, as well as in Phase Ib/II study for gastric cancer. It has an agreement with the Baker IDI Heart & Diabetes Institute to research, develop, and commercialize a portfolio of small molecule arginine modulators for oncology. The company is based in Carlton, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9824 5254

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.13 million
Cash FlowA$0.01 per share
Book ValueA$0.01 per share

Profitability

Miscellaneous

EmployeesN/A
Outstanding Shares3,609,850,112
Market Cap$79.42 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter.


Imugene (ASX:IMU) Frequently Asked Questions

What is Imugene's stock symbol?

Imugene trades on the ASX under the ticker symbol "IMU."

Has Imugene been receiving favorable news coverage?

Media headlines about IMU stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Imugene earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Imugene.

Who are some of Imugene's key competitors?

What other stocks do shareholders of Imugene own?

Who are Imugene's key executives?

Imugene's management team includes the folowing people:
  • Mr. Paul Edward Alexander Hopper, Exec. Chairman (Age 63)
  • Ms. Leslie Chong, CEO, MD & Exec. Director
  • Dr. Nicholas J. Ede, Chief Technology Officer
  • Mr. Phillip Allen Hains, CFO & Joint Company Sec. (Age 60)
  • Dr. Mark T. Marino, Chief Medical Officer (Age 59)

What is Imugene's stock price today?

One share of IMU stock can currently be purchased for approximately A$0.02.

How big of a company is Imugene?

Imugene has a market capitalization of $79.42 million and generates $4.13 million in revenue each year. View Additional Information About Imugene.

What is Imugene's official website?

The official website for Imugene is http://www.imugene.com/.

How can I contact Imugene?

The company can be reached via phone at 61 3 9824 5254.


MarketBeat Community Rating for Imugene (ASX IMU)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  24
MarketBeat's community ratings are surveys of what our community members think about Imugene and other stocks. Vote "Outperform" if you believe IMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel